Apex BiotechnologyTPE:1733 -0.17%81 Days Payable is 52.64 as of Dec. 2025, which is 14% above its 10-year median of 46.27. GuruFocus rates TPE:1733 with a GF Score™ of 81/100 and a GF Value™ of NT$30.08 (Fairly Valued). The stock has 2 warning signs investors should review. Among 699 Biotechnology companies, Apex Biotechnology ranks worse than 71.1% on this metric.
The historical rank and industry rank for Apex Biotechnology's Days Payable or its related term are showing as below:
TPE:1733'
s Days Payable Range Over the Past 10 Years
Min: 39.68 Med: 46.27 Max: 56.6
Current: 46.04
During the past 13 years, Apex Biotechnology's highest Days Payable was 56.60. The lowest was 39.68. And the median was 46.27.
TPE:1733's Days Payable is ranked worse than 71.1% of 699
companies
in the Biotechnology industry
Industry Median: 112.84
vs TPE:1733: 46.04
Apex Biotechnology's Days Payable
declined
from Dec. 2024 (56.14) to Dec. 2025 (52.64).
It may suggest that Apex Biotechnologyaccelerated paying its suppliers.
Apex Biotechnology Days Payable Related Terms
Apex Biotechnology Days Payable Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1733 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Apex Biotechnology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Days Payable distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Apex Biotechnology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apex Biotechnology (TPE:1733) has a Days Payable of 52.64 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Apex Biotechnology and its competitors. This is 14% above median its historical median of 46.27. Over the past decade, Apex Biotechnology's Days Payable has ranged from 39.68 to 56.60. According to the industry distribution chart, Apex Biotechnology ranks #497 out of 699 companies in the Biotechnology industry, placing it in the top 71.1%.
Is Apex Biotechnology's Days Payable too high?
Apex Biotechnology's current Days Payable of 52.64 is 14% above median its 10-year median of 46.27. Over the past 10 years, this metric has ranged from a low of 39.68 to a high of 56.60. The Biotechnology industry median Days Payable is 112.84. Apex Biotechnology's value of 52.64 is 53.3% below this industry median. Based on the distribution chart, Apex Biotechnology ranks #497 out of 699 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Apex Biotechnology has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #497 out of 699 companies for Days Payable. This places Apex Biotechnology in the lower half of its industry. The industry median Days Payable is 112.84. Apex Biotechnology's value of 52.64 is 53.3% below this benchmark. Historically, Apex Biotechnology's own Days Payable has ranged from 39.68 to 56.60 over the past decade. While the company's 10-year median is 46.27 vs. the industry median of 112.84, Apex Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apex Biotechnology's current Days Payable of 52.64 is 53.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Apex Biotechnology and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apex Biotechnology's current Days Payable is 52.64, which is 14% above median its own 10-year median of 46.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.08, compared to a current price of NT$29.90 — trading 0.6% below its estimated fair value. The current Days Payable is 52.64, which is 14% above median its 10-year median of 46.27 and 53.3% below the Biotechnology industry median of 112.84. Apex Biotechnology's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Days Payable is 52.64 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be undervalued.
The current stock price of NT$29.90 is trading 0.6% below its estimated GF Value™ of NT$30.08.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
Days Payable: 52.64 (14% above median its 10-year median of 46.27)
GF Value™: NT$30.08 vs. price of NT$29.90 (0.6% below fair value)
Industry Position: 53.3% below the Biotechnology median (#497 of 699)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
81GF Score
Get the complete analysis for TPE:1733
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
